SRx Health Solutions Shareholders Unanimously Approve Acquisition by Better Choice Company

Rhea-AI Summary

Better Choice Company (NYSE American: BTTR) announced that shareholders of SRx Health Solutions have overwhelmingly approved the proposed acquisition, with approximately 93% voting in favor. Better Choice will hold its Special Meeting on March 21, 2025, at 9:00 a.m. ET via live webcast for its stockholders to vote on the acquisition.

The record date for stockholder voting eligibility remains January 21, 2025, and stockholders as of this date can vote even if they have since sold their shares. Previously submitted proxies will be valid for all proposals unless properly revoked. The company plans to file and distribute a supplementary Proxy Statement with the SEC to ensure stockholders have adequate time to review updated materials and make informed voting decisions.

Positive

• 93% of SRx Health Solutions shareholders approved the acquisition
• Significant shareholder support indicates strong confidence in the merger

Negative

• None.

TAMPA, Fla., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Better Choice Company, Inc. (NYSE American: BTTR) (“Better Choice” or the “Company”), a pet health and wellness company, announced today that SRx Health Solutions, Inc. (“SRx”) held its special meeting of shareholders whereby approximately 93% voted in favor of the acquisition by the Company.

Better Choice will host its Special Meeting at 9:00 a.m., Eastern Time, on March 21, 2025, exclusively via live webcast at the following address: https://east.virtualshareholdermeeting.com/vsm/web?pvskey=BTTR2025SM. The record date for the stockholders to vote at the Special Meeting remains the close of business on January 21, 2025 (the “Record Date”).   Stockholders as of the Record Date can vote, even if they have subsequently sold their shares. Proxies previously submitted with respect to the Special Meeting will be voted on all proposals at the adjourned Special Meeting unless properly revoked in accordance with the procedures described in the Proxy Statement, and stockholders who have previously submitted a proxy or otherwise voted need not take any action.

The Company intends to file with the SEC and mail a supplement to the Proxy Statement in connection with the Special Meeting to provide Better Choice stockholders sufficient time to review the updated materials and cast their votes on a fully informed basis.

About Better Choice Company Inc.
Better Choice Company Inc. is a rapidly growing pet health and wellness company committed to leading the industry shift toward pet products and services that help dogs and cats live healthier, happier, and longer lives. We take an alternative, nutrition-based approach to pet health relative to conventional dog and cat food offerings and position our portfolio of brands to benefit from the mainstream trends of growing pet humanization and consumer focus on health and wellness. We have a demonstrated, multi-decade track record of success selling trusted pet health and wellness products and leverage our established digital footprint to provide pet parents with the knowledge to make informed decisions about their pet’s health. We sell the majority of our dog food, cat food and treats under the Halo brand, which is focused, respectively, on providing sustainably sourced kibble and canned food derived from real whole meat, and minimally processed raw-diet dog food and treats. For more information, please visit https://www.betterchoicecompany.com.

About SRX Health
SRx operates as a Canadian healthcare service provider specializing in the Specialty Pharmacy segment of the pharmaceutical industry. Distinguishing itself as a National Specialty Pharmacy provider, SRx concentrates on overseeing a patient's healthcare journey, spanning from acute pharmaceutical needs to chronic and rare disease management. This unique focus positions SRx to deliver a more holistic and integrated solution, catering to the requirements of both patients and key healthcare stakeholders. Our all-encompassing end-to-end offerings include wholesale/distribution facilities, patient support programs, infusion clinics, retail pharmacies, co-designed clinical programs, clinical trials, and diagnostic services.

Our strategic growth plan is forward-thinking and revolves around fostering increased collaboration with pharmaceutical manufacturers and prescribers. With a specific emphasis on the expanding market of chronic and rare diseases, we target specialty drugs associated with closed and limited distribution networks. The objective is to broaden their distribution and improve accessibility. Our overarching goal is to elevate our current presence from 34 to 100 specialty pharmacy locations across mid-sized population centers throughout Canada, thereby enhancing the scope of healthcare services and establishing new industry benchmarks. In the subsequent phase of SRx's evolution, we aim to extend our reach beyond the borders of Canada. Leveraging our comprehensive approach, we aspire to simplify healthcare on a global scale. For more information on SRx, please visit https://www.srxhealth.ca.

Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The words “believe,” “may,” “estimate,” “continue,” “anticipate,” “intend,” “should,” “plan,” “could,” “target,” “potential,” “is likely,” “will,” “expect” and similar expressions, as they relate to us, are intended to identify forward-looking statements. The Company has based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy and financial needs. Some or all of the results anticipated by these forward-looking statements may not be achieved. Further information on the Company’s risk factors is contained in our filings with the SEC. Any forward-looking statement made by us herein speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law.

Company Contact:
Better Choice Company, Inc.
Kent Cunningham, CEO

Investor Contact:
KCSA Strategic Communications
Valter Pinto, Managing Director
T: 212-896-1254
Valter@KCSA.com

FAQ

What percentage of SRx Health Solutions shareholders approved the Better Choice (BTTR) acquisition?

Approximately 93% of SRx Health Solutions shareholders voted in favor of the acquisition by Better Choice Company (BTTR).

When is Better Choice Company (BTTR) holding its Special Meeting for the SRx acquisition?

Better Choice Company will hold its Special Meeting on March 21, 2025, at 9:00 a.m. Eastern Time via live webcast.

What is the record date for Better Choice (BTTR) shareholders to vote on the SRx acquisition?

The record date for stockholders to vote at the Special Meeting is January 21, 2025.

Can Better Choice (BTTR) shareholders who sold their shares after January 21, 2025 still vote?

Yes, stockholders who owned shares as of the January 21, 2025 record date can still vote even if they have subsequently sold their shares.